Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer
Author:
Taha Koray Sahin,Alessandro Rizzo,Deniz Can Guven,Sercan Aksoy
Publication:
Cancer Treatment Reviews
© 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.